JUBILANT PHARMOVA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 716.8 INR | -0.43% |
|
+4.19% | +31.33% |
| 03/05 | Jubilant Pharmova Appoints CEO for Radiopharma Business | MT |
| 25/04 | Jubilant Pharmova Subsidiary's Canadian Manufacturing Unit Gets Five Observations from US FDA | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 61.3B 736M | Sales 2023 | 62.82B 754M | Capitalization | 44.42B 533M |
|---|---|---|---|---|---|
| Net income 2022 | 4.14B 49.71M | Net income 2023 | -610M -7.33M | EV / Sales 2022 | 1.37 x |
| Net Debt 2022 | 22.03B 265M | Net Debt 2023 | 26.44B 318M | EV / Sales 2023 | 1.13 x |
| P/E ratio 2022 |
14.9
x | P/E ratio 2023 |
-72.8
x | Employees | 5,778 |
| Yield 2022 |
1.29% | Yield 2023 |
1.79% | Free-Float | 36.33% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.43% | ||
| 1 week | +4.19% | ||
| Current month | +6.49% | ||
| 1 month | +2.15% | ||
| 3 months | +18.22% | ||
| 6 months | +64.88% | ||
| Current year | +31.33% |
1 week
677.35
740.80
1 month
658.90740.80
Current year
532.05740.80
1 year
318.50740.80
3 years
268.80925.00
5 years
230.001 046.75
10 years
116.101 046.75
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 46 | 23/17/23 | |
| Chief Executive Officer | 37 | 23/17/23 | |
Arvind Chokhany
DFI | Director of Finance/CFO | 52 | 01/21/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 67 | 01/82/01 | |
| Chairman | 71 | 21/78/21 | |
| Chief Executive Officer | 46 | 23/17/23 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 34 M€ | +3.87% | - | |
| 0.00% | 112 M€ | +5.41% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 18/24/18 | 716.8 | -0.43% | 1 001 |
| 17/24/17 | 719.8 | +0.01% | 23,460 |
| 16/24/16 | 719.8 | +0.55% | 36,805 |
| 15/24/15 | 715.8 | +4.09% | 32,406 |
| 14/24/14 | 687.7 | -0.04% | 18,512 |
Delayed Quote Bombay S.E., May 18, 2024 at 12:30 pm IST
More quotes
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
Sector
Pharmaceuticals
Calendar
31/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +31.33% | 1.37B | |
| +32.09% | 693B | |
| +29.39% | 584B | |
| -1.34% | 372B | |
| +20.34% | 332B | |
| +7.39% | 294B | |
| +14.25% | 239B | |
| -3.03% | 211B | |
| +10.02% | 210B | |
| +8.49% | 168B |
- Stock Market
- Equities
- JUBLPHARMA Stock
